Literature DB >> 27039388

Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses.

Simon Faissner1, Johanna Nikolayczik2, Andrew Chan2, Kerstin Hellwig2, Ralf Gold2, Min-Suk Yoon2, Aiden Haghikia3.   

Abstract

Patients suffering from multiple sclerosis (MS) are treated with high-dose intravenous steroids during acute relapses. In case of steroid refractory relapses, patients are treated with plasmapheresis or immunoadsorption. Until now data concerning the efficacy of both procedures are scarce. Visual evoked potentials (VEP), visual acuity and degree of remission of deficits caused by a relapse that had led to admission in MS patients (n = 48) treated with PLEX, IA or both in a single university centre setting were evaluated retrospectively. In a grouped analysis of patients treated with combined PLEX/IA, PLEX or IA alone, patients in all groups profited as assessed by VEP. Visual acuity also showed a trend towards a better performance, but lacked significance. In a subgroup analysis only concerning patients with initially pathological VEP there was a significant beneficial effect in the groups treated with PLEX/IA as well as in the group summarizing all patients. The combination of PLEX and IA provides a valid treatment option in steroid-refractory MS-relapses, and IA should be considered in acute relapses especially in patients with side effect of PLEX.

Entities:  

Keywords:  Immunoadsorption; Immunosuppressive treatment; Multiple sclerosis; Plasma exchange

Mesh:

Substances:

Year:  2016        PMID: 27039388     DOI: 10.1007/s00415-016-8105-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  14 in total

1.  Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.

Authors:  Zbigniew M Szczepiorkowski; Jeffrey L Winters; Nicholas Bandarenko; Haewon C Kim; Michael L Linenberger; Marisa B Marques; Ravindra Sarode; Joseph Schwartz; Robert Weinstein; Beth H Shaz
Journal:  J Clin Apher       Date:  2010       Impact factor: 2.821

2.  Plasmapheresis affects T helper type-1/T helper type-2 balance of circulating peripheral lymphocytes.

Authors:  H Goto; H Matsuo; S Nakane; H Izumoto; T Fukudome; C Kambara; N Shibuya
Journal:  Ther Apher       Date:  2001-12

3.  A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

Authors:  B G Weinshenker; P C O'Brien; T M Petterson; J H Noseworthy; C F Lucchinetti; D W Dodick; A A Pineda; L N Stevens; M Rodriguez
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

4.  Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Min-Suk Yoon; Andrew Chan; Ralf Gold
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

5.  A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.

Authors:  Wolfgang Köhler; Christoph Bucka; Reinhard Klingel
Journal:  J Clin Apher       Date:  2011-11-17       Impact factor: 2.821

6.  Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.

Authors:  B O Khatri; S Man; G Giovannoni; A P Koo; J-C Lee; B Tucky; F Lynn; S Jurgensen; J Woodworth; S Goelz; P W Duda; M A Panzara; R M Ransohoff; R J Fox
Journal:  Neurology       Date:  2009-02-03       Impact factor: 9.910

7.  Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis.

Authors:  J-H Yeh; S-H Wang; P-J Chien; C-M Shih; H-C Chiu
Journal:  Eur J Neurol       Date:  2009-07-14       Impact factor: 6.089

Review 8.  Immunoadsorption in steroid-refractory multiple sclerosis.

Authors:  Michael J Koziolek; Bernd Kitze; Johannes Mühlhausen; Gerhard A Müller
Journal:  Atheroscler Suppl       Date:  2013-01       Impact factor: 3.235

9.  Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.

Authors:  Werner Wenning; Aiden Haghikia; Jörg Laubenberger; David B Clifford; Peter F Behrens; Andrew Chan; Ralf Gold
Journal:  N Engl J Med       Date:  2009-09-10       Impact factor: 91.245

Review 10.  Therapies for multiple sclerosis: translational achievements and outstanding needs.

Authors:  Aiden Haghikia; Reinhard Hohlfeld; Ralf Gold; Lars Fugger
Journal:  Trends Mol Med       Date:  2013-04-10       Impact factor: 11.951

View more
  8 in total

1.  Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis.

Authors:  Lidia Stork; David Ellenberger; Tim Beißbarth; Tim Friede; Claudia F Lucchinetti; Wolfgang Brück; Imke Metz
Journal:  JAMA Neurol       Date:  2018-04-01       Impact factor: 18.302

2.  Visual Outcomes of Plasma Exchange Treatment of Steroid-Refractory Optic Neuritis: A Retrospective Monocentric Analysis.

Authors:  Nic Skorupka; Andrei Miclea; Katarzyna Aleksandra Jalowiec; Christoph Bocksrucker; Nicole Kamber; Andrew Chan; Behrouz Mansouri Taleghani; Robert Hoepner; Anke Salmen
Journal:  Transfus Med Hemother       Date:  2019-11-14       Impact factor: 3.747

3.  Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.

Authors:  Mark A Agius; Gabriela Klodowska-Duda; Maciej Maciejowski; Andrzej Potemkowski; Jing Li; Kaushik Patra; Jacob Wesley; Soraya Madani; Gerard Barron; Eliezer Katz; Armando Flor
Journal:  Mult Scler       Date:  2017-11-16       Impact factor: 6.312

4.  Therapeutic Plasma Exchange in Multiple Sclerosis and Autoimmune Encephalitis: a Comparative Study of Indication, Efficacy and Safety.

Authors:  Tobias Moser; Gayane Harutyunyan; Anush Karamyan; Ferdinand Otto; Carola Bacher; Vaclav Chroust; Markus Leitinger; Helmut F Novak; Eugen Trinka; Johann Sellner
Journal:  Brain Sci       Date:  2019-10-09

5.  Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses.

Authors:  Steffen Pfeuffer; Leoni Rolfes; Eike Bormann; Cristina Sauerland; Tobias Ruck; Matthias Schilling; Nico Melzer; Marcus Brand; Refik Pul; Christoph Kleinschnitz; Heinz Wiendl; Sven G Meuth
Journal:  J Clin Med       Date:  2019-12-22       Impact factor: 4.241

6.  Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial.

Authors:  Johannes Dorst; Tanja Fangerau; Daniela Taranu; Pia Eichele; Jens Dreyhaupt; Sebastian Michels; Joachim Schuster; Albert C Ludolph; Makbule Senel; Hayrettin Tumani
Journal:  EClinicalMedicine       Date:  2019-11-14

7.  Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis.

Authors:  Mark Lipphardt; Manuel Wallbach; Michael J Koziolek
Journal:  J Clin Med       Date:  2020-05-25       Impact factor: 4.241

Review 8.  The Role of Antibodies in the Pathogenesis of Multiple Sclerosis.

Authors:  Xiaoli Yu; Michael Graner; Peter G E Kennedy; Yiting Liu
Journal:  Front Neurol       Date:  2020-10-20       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.